Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS
Acumen Pharmaceuticals — Investor Presentation (July 2007)
17 slides from Acumen Pharmaceuticals's investor presentation, July 2007
Slide 1: Acumen Pharmaceuticals
Acumen Pharmaceuticals Developing disease-modifying drugs that block and reverse memory loss in Alzheimer’s disease
Slide 2: Acumen in a nutshell
Acumen in a nutshell z z GOAL –– Drugs that block, reverse Alzheimer ’s Alzheimer’s z z TARGET: Stop ADDLs –– Small molecules: Acumen –– Antibodies: Merck –– Vaccines: Merck (option) z ADVANTAGE z –– Chemistry –– Scientific expertise –– Key ADDL IP
Slide 3: Agenda
Agenda z Why ADDLs? z Why Acumen? z What’s in the pipeline? z What’s next?
Slide 4: ADDLs: soluble Aβ oligomers (1996)
“ADDLs” … soluble Aβ oligomers (1996) 12-mer Low- n-mer 4oC 37oC •Form at < 10 nM Aβ 1-42 •Globular molecules, metastable •Heterogeneous sizes, certain preferred forms Chromy Chromy et et al, al, 2003 2003
Slide 5: ADDLs are >70x elevated in AD brain
ADDLs are >70x elevated in AD brain 4 Control 10 3 10 ADDL Concentration (fM) 2 10 1 10 AD 0 10 -1 10 -2 10 Control AD population Diagnosed
Slide 6: ADDLs are the immediate cause of memory loss
ADDLs are the immediate cause of memory loss. Papers available. ADDLs ADDLs alone… alone… Stopping Stopping ADDLs… ADDLs… 9 9Bind Bind to to synapses synapses 99 Restores Restores LTP LTP 9 9Impair Impair LTP LTP 9 9 Stops Stops Tau-P Tau-P 9 9Initiate Initiate Tau-P Tau-P 9 9 Protects Protects CA1
Slide 7: Agenda
Agenda z Why ADDLs? z Why Acumen? z What’s in the pipeline? z What’s next?
Slide 8: Acumen can now…
Acumen can now… z z Stop ADDL assembly z z Stop ADDL receptor binding z z Stop ADDL-induced tau phosphorylation ADDL-induced
Slide 9: Acumen IP… vetted by Merck
Acumen IP… vetted by Merck Amyloid β-Derived Diffusible Ligands ADDLS “soluble non-fibrillar amyloid β protein assembly comprising at least from 3-24 amyloid β proteins and which exhibits neurotoxic activity” z Acumen has fundamental patents z Merck conducted diligence on our IP z Merck executed a v
Slide 10: Acumen is now focused on chemistry
Acumen is now focused on chemistry Founded, IP from Opened R&D facility Northwestern & USC in SSF Virtual Company, strengthened IP Small molecule portfolio, solidified the scientific story programs initiated 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 $1.5M seed investment Merck deal: mAb
Slide 11: Agenda
Agenda z Why ADDLs? z Why Acumen? z What’s in the pipeline? z What’s next?
Slide 12: 3 Chemistry Programs
3 Chemistry Programs Reverse Receptor Antagonist Antagonist Aβ-monomer Aβ-Low-n-mers Aβ-dodecamer ADDLs MAP2 DAPI Assembly Blocker
Slide 13: First lead series
First lead series z z 3 scaffold variants, common pharmacophore z z Sub µµM Kiiapp M potency ((K app ~ 150 nM) z z Non -aggregating, good solubility Non-aggregating, z z Rule of 5 compliant z z No apparent neuronal toxicity z z Chemically tractable z z Novel structures z z Dose dependent, reversible
Slide 14: Lead series shows dose dependent blocking of ADDL binding to neurons
Lead series shows dose dependent blocking of ADDL binding to neurons 20uM cmpd 10uM cmpd 20µm 20µm no cmpd Punctuate binding of ADDLs to dentrites 20µm
Slide 15: Agenda
Agenda z Why ADDLs? z Why Acumen? z What’s in the pipeline? z What’s next?
Slide 16: Acumen's Partnering Objectives
Acumen’s Partnering Objectives z z Partner one of three programs z z Advance leads to IND z z Parallel screen proprietary libraries to expand IP and diversify leads z z Cash to fund lead development z z Access development capabilities and expertise
Slide 17: Additional information
Additional information David Summa – President & CEO Grant Krafft – Chief Science Officer William Goure – Chief Operating Officer Extensive bibliography and issued patents available upon request Telephone: 650-875-7700 Email: info@acumenpharm.com Web: www.acumenpharm.com
Acumen Pharmaceuticals — Investor Presentation (July 2007) on 6ix